It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
It is unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can directly infect human kidney, thus leading to acute kidney injury (AKI). Here, we perform a retrospective analysis of clinical parameters from 85 patients with laboratory-confirmed coronavirus disease 2019 (COVID-19); moreover, kidney histopathology from six additional COVID-19 patients with post-mortem examinations was performed. We find that 27% (23/85) of patients exhibited AKI. The elderly patients and cases with comorbidities (hypertension and heart failure) are more prone to develop AKI. Haematoxylin & eosin staining shows that the kidneys from COVID-19 autopsies have moderate to severe tubular damage. In situ hybridization assays illustrate that viral RNA accumulates in tubules. Immunohistochemistry shows nucleocapsid and spike protein deposits in the tubules, and immunofluorescence double staining shows that both antigens are restricted to the angiotensin converting enzyme-II-positive tubules. SARS-CoV-2 infection triggers the expression of hypoxic damage-associated molecules, including DP2 and prostaglandin D synthase in infected tubules. Moreover, it enhances CD68+ macrophages infiltration into the tubulointerstitium, and complement C5b-9 deposition on tubules is also observed. These results suggest that SARS-CoV-2 directly infects human kidney to mediate tubular pathogenesis and AKI.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to acute kidney injury. The authors describe that SARS-COV-2 can directly infect human kidney, possibly mediating tubular pathogenesis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Third Military Medical University, Institute of Immunology, PLA, Chongqing, P. R. China (GRID:grid.410570.7) (ISNI:0000 0004 1760 6682); Department of Medical Laboratory Center, General Hospital of Central Theater Command, Wuhan, P. R. China (GRID:grid.417279.e); Hubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan, P. R. China (GRID:grid.417279.e)
2 Third Military Medical University, Institute of Immunology, PLA, Chongqing, P. R. China (GRID:grid.410570.7) (ISNI:0000 0004 1760 6682)
3 Huazhong University of Science and Technology, Department of Forensic Medicine, Tongji Medical College, Wuhan, P. R. China (GRID:grid.33199.31) (ISNI:0000 0004 0368 7223)
4 Department of Medical Laboratory Center, General Hospital of Central Theater Command, Wuhan, P. R. China (GRID:grid.417279.e)
5 Renmin Hospital of Wuhan University, Department of Nephrology, Wuhan, P. R. China (GRID:grid.412632.0) (ISNI:0000 0004 1758 2270)
6 989th Hospital of PLA, Department of Pathology, Luoyang, P. R. China (GRID:grid.412632.0)
7 Hubei Chongxin Judicial Expertise Center, Wuhan, P. R. China (GRID:grid.412632.0)
8 Guangzhou KingMed Center for Clinical Laboratory Co., Ltd., Guangzhou, P. R. China (GRID:grid.417279.e)